Chemotherapy versus hormonal adjuvant treatment in premenopausal patients with breast cancer

This publication has 17 references indexed in Scilit:

• The ZEBRA study: Early benefits in quality of life in goserelin-treated vs CMF-treated pre-/perimenopausal patients with node-positive early breast cancer
  European Journal Of Cancer, 2001
• Combined Tamoxifen and Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Versus LHRH Agonist Alone in Premenopausal Advanced Breast Cancer: A Meta-Analysis of Four Randomized Trials
  Journal of Clinical Oncology, 2001
• Combined Treatment With Buserelin and Tamoxifen in Premenopausal Metastatic Breast Cancer: a Randomized Study
  JNCI Journal of the National Cancer Institute, 2000
• Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
  The Lancet, 2000
• Comparison of adjuvant therapy with tamoxifen and goserelin vs. CMF in premenopausal stage I and II hormone-responsive breast cancer patients: four-year results of Austrian Breast Cancer Study Group (ABCSG) trial 5
  European Journal Of Cancer, 1999
• Subsets within the chemotherapy overview
  The Lancet, 1998
• Polychemotherapy for early breast cancer: an overview of the randomised trials
  The Lancet, 1998
• Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the international Breast Cancer Study Group (IBCSG) trial VI
  European Journal Of Cancer, 1998
• Ovarian ablation in early breast cancer: overview of the randomised trials
  The Lancet, 1996
• Premenopausal oopherectomy versus CMF chemotherapy In stage II breast carcinoma
  The Lancet, 1993